Page last updated: 2024-12-10

boc-tyr(s03)-nle-gly-trp-nle-asp-2-phenylethyl ester

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

JMV 180: distinguishes high-affinity cholecystokinin receptors from low-affinity cholecystokinin receptors; RN given refers to (S)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3035023
MeSH IDM0162994

Synonyms (10)

Synonym
jmv 180
cck-jmv-180
l-aspartic acid, n-(n-(6-((n-(n-(6-((2-(((1,1-dimethylethoxy)carbonyl)amino)-1-oxo-3-(4-(sulfooxy)phenyl)propyl)amino)-1-oxohexyl)glycyl)-l-tryptophyl)amino)-1-oxohexyl)-l-alpha-aspartyl)-, 1-(2-phenylethyl) ester, (s)-
butyloxycarbonyl-tyrosyl-aminohexanoyl-glycyl-tryptophyl-aminohexanoyl-aspartyl phenylethyl ester
boc-tyr(s03)-nle-gly-trp-nle-asp-2-phenylethyl ester
boc-tyr(so3) ahx-gly-trp-ahx-asp2 phenylethyl ester
119733-42-5
DTXSID70152565
(6s,19s,29s,32s)-19-((1h-indol-3-yl)methyl)-29-(carboxymethyl)-2,2-dimethyl-4,7,14,17,20,27,30-heptaoxo-32-(phenethoxycarbonyl)-6-(4-(sulfooxy)benzyl)-3-oxa-5,8,15,18,21,28,31-heptaazatetratriacontan-34-oic acid
(3s)-4-[[(2s)-3-carboxy-1-oxo-1-(2-phenylethoxy)propan-2-yl]amino]-3-[6-[[(2s)-3-(1h-indol-3-yl)-2-[[2-[6-[[(2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-(4-sulfooxyphenyl)propanoyl]amino]hexanoylamino]acetyl]amino]propanoyl]amino]hexanoylamino]-4-oxob

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"When pancreatic acini are incubated with increasing concentrations of cholecystokinin octapeptide (CCK-8) the dose-response curve for stimulation of enzyme secretion increases, reaches a maximum and then decreases."( CCK-JMV-180: a peptide that distinguishes high-affinity cholecystokinin receptors from low-affinity cholecystokinin receptors.
Gardner, JD; Jensen, RT; Martinez, J; Sharp, CM; Stark, HA; Sutliff, VE, 1989
)
0.28
" Comparison of the dose-response curve for calcium mobilization and amylase release stimulated by CCK-8 or CCK-JMV-180 indicates that very low concentrations of each peptide stimulate amylase release without causing detectable calcium mobilization."( Receptor occupation, calcium mobilization, and amylase release in pancreatic acini: effect of CCK-JMV-180.
Beaven, MA; Gardner, JD; Jensen, RT; Martinez, J; Sato, S; Stark, HA, 1989
)
0.28
" The downward portion of the dose-response curve has been referred to as "high-dose" inhibition."( Novel CCK analogues and bombesin: a detailed analysis between phosphoinositide breakdown and high-dose inhibition of pancreatic enzyme secretion in three rodent species.
Bianchi, BR; Lin, CW; Miller, TR; Witte, DG, 1994
)
0.29
" The comparison of CCK-8 and JMV-180 dose-response curves of amylase release to those of PtdIns and PtdOH labelling with [(32)P]-Pi showed the existence of an amplification mechanism between phospholipase C and amylase release for both agonists."( The cholecystokinin analogues JMV-180 and CCK-8 stimulate phospholipase C through the same binding site of CCK(A) receptor in rat pancreatic acini.
Claro, E; Ramos, B; Salido, GM; Sarri, E, 2001
)
0.31
" CCK8 generated a biphasic secretion dose-response curve, and high concentrations increased intracellular active trypsin levels."( Secretagogues differentially activate endoplasmic reticulum stress responses in pancreatic acinar cells.
Kubisch, CH; Logsdon, CD, 2007
)
0.34
" With both strategies, dose-response curves were generated for the natural agonist CCK-8S, the partial agonist JMV-180 as well as the antagonist lorglumide."( Time-resolved quantitative analysis of CCK1 receptor-induced intracellular calcium increase.
De Vos, WH; Smagghe, G; Staljanssens, D; Van Camp, J; Willems, P, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (72)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (5.56)18.7374
1990's52 (72.22)18.2507
2000's12 (16.67)29.6817
2010's4 (5.56)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.20 (24.57)
Research Supply Index4.36 (2.92)
Research Growth Index5.55 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (5.19%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other73 (94.81%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]